Core Viewpoint - Company focuses on enhancing its core businesses in agricultural protection and pharmaceutical CDMO through overseas base expansion and R&D innovation, while steadily advancing its new energy business for long-term development [2] Group 1: Investor Relations Activity - On December 19, the company held an investor relations activity with five institutions, including Guohai Securities and Nomura Asset Management, discussing key issues such as agricultural protection business layout, pharmaceutical CDMO development, R&D innovation direction, and capital operation plans [1] - The meeting was attended by the company's Senior Vice President and Secretary of the Board, Chen Feibiao, and Securities Affairs Representative Dai Yiyi [1] Group 2: Agricultural Protection Business - The company plans to enhance its overseas base layout, establishing Malaysia as a second overseas base for a differentiated supply chain, collaborating with production bases in China and the UK [1] - The agricultural protection industry is highly concentrated, and the company has formed long-term strategic partnerships with several international agrochemical companies, covering all stages of the product lifecycle [1] Group 3: Pharmaceutical Business - The pharmaceutical business is expanding its coverage and deepening cooperation, focusing on products under patent protection [1] - The company aims for steady long-term growth by enhancing technical capabilities to strengthen customer cooperation [1] Group 4: R&D Innovation - The company is expanding into emerging fields such as peptide and radioactive drugs, while continuing to develop small molecule CDMO and starting materials [1] - The team has experience in delivering peptide and PEG linker products, optimizing synthesis routes based on customer needs [1] Group 5: CDMO Core Competitiveness - The company's core competitiveness lies in strong technological innovation, high safety and environmental standards, efficient production management, and a strict quality assurance system [1] - These advantages have earned recognition from leading global agricultural and pharmaceutical companies, ensuring stable and long-term cooperation [1] Group 6: Capital Operation - Currently, the company has no plans for secondary market financing, focusing capital expenditures on the construction of coastal and Malaysian bases [1] - As of the first three quarters of 2025, the company reported a net cash flow from operating activities of approximately 900 million yuan, sufficient to support planned capital expenditures [1] Group 7: New Energy Business - The company primarily sells LiFSI and electrolyte products, while improving the technology for lithium hexafluorophosphate [1] - It is expected that the new energy business will achieve significant revenue breakthroughs in 2025, leveraging its R&D and production advantages in fine chemicals [1]

每经AI快讯，联化科技（SZ 002250，收盘价：12.19元）发布公告称，2025年12月19日，联化科技接受 国海证券等投资者调研，公司高级副总裁、董秘陈飞彪，证券事务代表戴依依参与接待，并回答了投资 者提出的问题。 截至发稿，联化科技市值为110亿元。 每经头条（nbdtoutiao）——大洗牌！AI手机大战开启，豆包率先放大招！苹果、谷歌"慢半拍"？业 内：苹果是"最保守的大玩家" （记者 曾健辉） 2025年1至6月份，联化科技的营业收入构成为：工业占比99.64%，其他业务占比0.36%。 ...

Group 1 - The core viewpoint of the news is that Guohai Securities has been recognized for its innovative financial practices, particularly in issuing bonds to support small and micro enterprises and the Belt and Road Initiative in Guangxi [1][2][3] Group 2 - Guohai Securities has been awarded for its role in issuing the first phase of short-term corporate bonds for the Guangxi Beibu Gulf International Port Group, which aligns with the Belt and Road Initiative [1] - The company has successfully issued the first private placement bond for small and micro enterprises in Guangxi, with a historically low interest rate, aimed at supporting local industries such as manufacturing and food supply [2] - The issuance of the Belt and Road bonds has strengthened Guangxi's position as a key player in the initiative, reducing financing costs for enterprises and enhancing regional economic development [3]

Core Viewpoint - The year 2026 is projected to be a turning point for China's economy, moving away from low inflation and establishing a "new equilibrium" as per the consensus among major securities firms [1]. Group 1: Macroeconomic Growth and Price Recovery - Major securities firms, including China Merchants, Ping An, and West Securities, agree that the Chinese economy will emerge from the low inflation phase, with expectations of nominal GDP growth recovery driven by price factor improvements [1][5]. - The "anti-involution" policy is expected to limit supply, combined with the pig cycle bottoming out and PPI turning positive, which will be key in improving corporate profitability and nominal GDP [1][5][6]. Group 2: Structural Transition and New Growth Drivers - 2026 is seen as a critical juncture for the transition between old and new growth drivers, with real estate investment entering a bottoming phase while AI, data center energy demand, and high-end manufacturing are expected to become substantial growth engines [1][5][21]. - The consensus is that the economy will experience a "new-old relay" with significant changes in investment structures, particularly in manufacturing and real estate [1][21]. Group 3: Demand-Side Drivers - There is a divergence in views regarding demand-side drivers; some firms like Minsheng and Northeast Securities believe external demand will outperform internal demand, while others like West Securities and Shenwan Hongyuan predict a shift towards internal demand dominance [1][5][21]. Group 4: Asset Allocation and Market Style Predictions - Opinions on asset allocation and market style are highly varied, with Haitong International being the most optimistic, predicting a 40% increase in the Shanghai Composite Index based on "value re-evaluation" logic [2][50]. - China Merchants Securities anticipates a shift from "policy-driven" to "profit-driven" market dynamics, while others suggest a more balanced focus on both growth and cyclical opportunities [2][21]. Group 5: Key Predictions from Securities Firms - China Merchants Securities predicts a recovery in corporate profits and a shift in policy focus towards enhancing development quality, with manufacturing investment expected to grow by 5% and real estate investment's decline narrowing to -8% [5][10]. - Ping An Securities emphasizes the importance of price recovery, forecasting CPI to rise to 0.6% and PPI to narrow its decline significantly [16][18]. - West Securities expects nominal GDP growth to accelerate, driven by inflation recovery and the emergence of new growth forces [21][23]. Group 6: External Environment and Trade Dynamics - The external environment is expected to improve, with strong export performance contributing significantly to GDP growth, projected to be around 40%-50% from actual export growth [11][44]. - The report from Northeast Securities highlights that external demand will recover before internal demand, with exports expected to grow by approximately 7% [44][45].

Core Viewpoint - The pet industry is experiencing intensified competition, and long-term growth driven by marketing expenses is unsustainable. The current market demands enhanced operational capabilities in supply chain control, new product development, and refined marketing strategies. Leading brands have established significant advantages over smaller and mid-tier brands, leading to a clearer competitive landscape in the pet industry. The recommendation for the pet food industry remains "recommended" [1]. Group 1: Market Evolution - The domestic pet market has undergone significant channel transformations over the past two decades, shifting from offline to online and from distribution to direct sales, with domestic brands rapidly developing during the e-commerce boom [2]. - From 2003 to 2012, the Chinese pet industry was dominated by offline sales and distribution, with foreign brands holding market power while domestic brands began to emerge. The period from 2012 to 2018 saw e-commerce, exemplified by "Taobao" and "Double Eleven," reshape the industry landscape [2]. - Since 2019, platforms like Douyin have driven brand development through content-driven strategies and refined channel upgrades [2]. Group 2: Online and Offline Channels - Online channels have become the primary sales avenue for pet food, leveraging e-commerce platforms for rapid growth and serving as the main route for domestic brands to reach mainstream consumers [3]. - Offline channels are essential for building trust and providing service-oriented consumption experiences, primarily through specialized stores and veterinary clinics, which offer product trials and professional consultations [4]. Group 3: Channel Strategy and Key Factors - Efficiency improvement and brand building are critical in channel competition, focusing on enhancing brand recognition. As the industry faces slowing growth and high customer acquisition costs, brands must shift from broad expansion to deep engagement with users throughout their lifecycle [5]. - The core direction for traditional channels will be the online transformation, emphasizing precise targeting and refined operations [5].

2025 年 12 月 19 日 晨会纪要 研究所： 证券分析师： 余春生 S0350513090001 yucs@ghzq.com.cn [Table_Title] 晨会纪要 ——2025 年第 216 期 观点精粹: 最新报告摘要 证券研究报告 1、最新报告摘要 1.1、宠物行业专题报告：复盘宠物行业渠道变革，品牌精细化运营进入新阶 段——系列研究之三--行业 PPT 报告 分析师：王思言 S0350524010001 分析师：程一胜 S0350521070001 本篇报告解决了以下核心问题：1、深度复盘国内宠物行业二十年渠道变迁的底层逻辑；2、辨析线上流量存 量博弈与线下服务壁垒的差异化价值；3、探寻在流量成本高企的当下，品牌如何通过渠道精细化运营与策略 分层实现突围。 复盘二十年国内宠物市场渠道变迁，经历了由线下到线上、由经销到直销的转变，借助电商渠道红利期，国产 宠物品牌发展迅速。2003-2012 年，中国宠物行业处于线下为王、经销主导的初步发展期，市场格局由外资 品牌掌控，国产宠物品牌起步；2012-2018 年，以"淘天系"及"双十一"为代表的电商红利，成为重塑宠 物行业格局的核心驱动力。20 ...

Core Viewpoint - Guohai Securities' report indicates that East China Pharmaceutical's dual-target GLP-1 is progressing smoothly, with a positive outlook on the weight loss market development [1] Group 1: Clinical Trial Results - The company's wholly-owned subsidiary, Zhongmei East China, has developed an innovative long-acting agonist HDM1005, targeting both GLP-1 and GIP receptors, which has shown positive results in Phase II clinical trials for weight management in China [1] - The weight loss effects of HDM1005 were significant, with the 0.5mg, 1.0mg, 2.0mg, and 4.0mg groups showing weight changes of -7.47%, -9.73%, -13.31%, and -13.28% respectively after 22 weeks, compared to a -2.46% change in the placebo group [1] - In addition to weight reduction, HDM1005 also demonstrated significant improvements in other cardiovascular and metabolic indicators, including glucose metabolism, blood pressure, and blood lipids [1] Group 2: Company Positioning - The company is recognized as a leading domestic prescription drug enterprise, with a rich product pipeline and industry-leading channel and brand capabilities [1] - The company is expected to achieve coordinated growth through both internal and external development strategies [1]

Group 1 - The pace of cash dividends among listed securities firms has accelerated significantly as the year-end approaches, with multiple firms announcing dividend plans in mid-December [1] - Specific announcements include Changcheng Securities planning to distribute a cash dividend of 0.76 yuan per 10 shares, totaling 307 million yuan, with a payment date of December 19 [1] - Other firms like Xingye Securities and Shouchuang Securities have also announced substantial cash dividends, contributing to a total expected payout of over 1 billion yuan from at least five firms in the last two weeks [1] Group 2 - The total cash dividends distributed by listed securities firms in 2023 has approached 55 billion yuan, with 13 firms, including Guotai Junan and Huatai Securities, each distributing over 1 billion yuan [2] - Guotai Junan leads with a dividend payout of approximately 7.5 billion yuan, while Huatai Securities,招商证券, and 中信证券 have also exceeded 4 billion yuan in dividends [2] Group 3 - As of December 16, 2023, 35 listed securities firms have announced dividend plans for 2025, with a total proposed payout exceeding 21.8 billion yuan, led by 中信证券 with nearly 4.3 billion yuan [4] - The announced dividends for 2025 include significant amounts from firms such as Guotai Haitong and Huatai Securities, with several firms also planning mid-term dividends [5][6]

Core Insights - The 2025 Securities Times Best Analyst results were announced, highlighting the top-performing teams and analysts in various categories [1] - The event saw participation from nearly 50 securities firms and over 1300 domestic and international institutions, with more than 800 institutions qualifying to vote [1] Group 1: Top Analysts and Teams - The macroeconomic first place was awarded to the team led by Guo Lei from GF Securities [1] - The top strategy research team was also from GF Securities, led by Liu Chenming [1] - The top analyst in the gold category was Sun Yuanyuan from Industrial Securities [1] Group 2: Participation and Voting - The voting institutions included over 160 public fund institutions, 30 insurance asset management companies, and 100 insurance companies, among others [1] - The total assets managed by the participating institutions exceeded 100 trillion yuan [1] Group 3: Performance Rankings - The rankings for various research teams in different categories were detailed, with GF Securities consistently performing well across multiple sectors [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]

在畅通经济循环层面，杨仁文进一步分析，发展新质生产力，是激发有效需求、畅通国内大循环的强劲 引擎。近年来，中国经济面临供强需弱的发展问题。"十五五"时期需重视新质生产力通过创造新产品、 新服务、新场景、新业态，激发和引领新消费需求的重要作用。同时，新质生产力催生的智慧物流、工 业互联网等也能极大提升流通效率，畅通国民经济循环。此外，发展新质生产力要求市场化要素跨区配 置，也将推动消除地方保护和市场分割，破除阻碍全国统一大市场建设的卡点堵点，加快全国统一大市 场推进建设。 本报讯 （记者周尚伃）2026年是"十五五"规划的开局之年。近日，国海证券首席研究官兼研究所所长 杨仁文发文表示，"十五五"时期是基本实现社会主义现代化夯实基础、全面发力的关键时期，战略机遇 和风险挑战并存。为破解国内发展面临的诸多结构性难题，需坚定不移发展新质生产力，推动高质量发 展。 "发展新质生产力，是解决发展不平衡不充分问题的重要途径。"在杨仁文看来，当前，我国区域发展差 距依然客观存在。"十五五"时期，要增强区域发展协调性，促进东中西、南北方协调发展，需因地制宜 发展新质生产力，通过新质生产力强大的渗透性和赋能效应，打破地理空间限制 ...